- Home
- TSLX vs ZLAB Comparison
TSLX vs ZLAB Comparison
Compare TSLX & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSLX
- ZLAB
- Stock Information
- Founded
- TSLX 2010
- ZLAB 2013
- Country
- TSLX United States
- ZLAB China
- Employees
- TSLX N/A
- ZLAB N/A
- Industry
- TSLX Investment Managers
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- TSLX Finance
- ZLAB Health Care
- Exchange
- TSLX Nasdaq
- ZLAB Nasdaq
- Market Cap
- TSLX 2.1B
- ZLAB 3.6B
- IPO Year
- TSLX 2014
- ZLAB 2017
- Fundamental
- Price
- TSLX $23.83
- ZLAB $35.17
- Analyst Decision
- TSLX Strong Buy
- ZLAB Buy
- Analyst Count
- TSLX 8
- ZLAB 5
- Target Price
- TSLX $22.69
- ZLAB $54.28
- AVG Volume (30 Days)
- TSLX 558.0K
- ZLAB 987.9K
- Earning Date
- TSLX 07-30-2025
- ZLAB 08-05-2025
- Dividend Yield
- TSLX 8.74%
- ZLAB N/A
- EPS Growth
- TSLX N/A
- ZLAB N/A
- EPS
- TSLX 1.89
- ZLAB N/A
- Revenue
- TSLX $481,092,000.00
- ZLAB $418,326,000.00
- Revenue This Year
- TSLX N/A
- ZLAB $44.07
- Revenue Next Year
- TSLX N/A
- ZLAB $49.13
- P/E Ratio
- TSLX $12.60
- ZLAB N/A
- Revenue Growth
- TSLX 4.73
- ZLAB 43.72
- 52 Week Low
- TSLX $18.58
- ZLAB $16.01
- 52 Week High
- TSLX $23.98
- ZLAB $44.34
- Technical
- Relative Strength Index (RSI)
- TSLX 63.19
- ZLAB 48.52
- Support Level
- TSLX $22.76
- ZLAB $34.55
- Resistance Level
- TSLX $23.98
- ZLAB $36.73
- Average True Range (ATR)
- TSLX 0.35
- ZLAB 1.35
- MACD
- TSLX 0.01
- ZLAB -0.61
- Stochastic Oscillator
- TSLX 85.54
- ZLAB 7.35
About TSLX Sixth Street Specialty Lending Inc.
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.